How Analysts Feel About DexCom, Inc. (NASDAQ:DXCM)?

DexCom, Inc. (NASDAQ:DXCM) LogoInvestors sentiment increased to 1.22 in 2018 Q2. Its up 0.07, from 1.15 in 2018Q1. It improved, as 21 investors sold DexCom, Inc. shares while 82 reduced holdings. 46 funds opened positions while 80 raised stakes. 88.54 million shares or 9.89% less from 98.26 million shares in 2018Q1 were reported.
Glob X Limited Liability stated it has 73,075 shares. Jefferies Lc holds 0.01% in DexCom, Inc. (NASDAQ:DXCM) or 27,148 shares. Frontier Mngmt Limited Liability Co, Massachusetts-based fund reported 662,576 shares. 9,800 were accumulated by Great West Life Assurance Can. Jpmorgan Chase & holds 0.06% or 2.89M shares in its portfolio. Savant Cap Ltd Liability Corporation invested in 37,413 shares. Gilder Gagnon Howe & Limited Liability reported 596,730 shares. 58,381 are held by Kbc Gp Nv. Stephens Invest Ltd Llc owns 320,310 shares. State Board Of Administration Of Florida Retirement System reported 0.03% in DexCom, Inc. (NASDAQ:DXCM). Clinton Gru reported 2,117 shares. 1.27M were accumulated by Invesco Ltd. Cubist Systematic Strategies Llc has invested 0.02% in DexCom, Inc. (NASDAQ:DXCM). Td Asset Mngmt holds 0.01% of its portfolio in DexCom, Inc. (NASDAQ:DXCM) for 79,473 shares. Capital stated it has 5.18 million shares.

Since June 12, 2018, it had 0 insider purchases, and 44 sales for $46.46 million activity. $5.47M worth of DexCom, Inc. (NASDAQ:DXCM) was sold by MOY JEFFREY. Murphy Patrick Michael sold $1.55 million worth of stock. The insider Pacelli Steven Robert sold $435,843. 11,161 shares were sold by SAYER KEVIN R, worth $1.39M on Monday, October 8. DOUBLEDAY RICHARD sold $223,466 worth of stock. Another trade for 4,258 shares valued at $627,294 was made by ACE HEATHER S on Friday, November 9.

DexCom, Inc. (NASDAQ:DXCM) Ratings Coverage

Among 13 analysts covering DexCom (NASDAQ:DXCM), 9 have Buy rating, 0 Sell and 4 Hold. Therefore 69% are positive. DexCom had 18 analyst reports since June 8, 2018 according to SRatingsIntel. The firm earned “Outperform” rating on Tuesday, October 23 by Raymond James. The firm has “Buy” rating given on Wednesday, August 15 by Bank of America. The rating was upgraded by Goldman Sachs to “Neutral” on Friday, October 19. BMO Capital Markets maintained DexCom, Inc. (NASDAQ:DXCM) on Thursday, August 2 with “Outperformer” rating. Morgan Stanley maintained it with “Equal-Weight” rating and $150 target in Thursday, October 11 report. The stock of DexCom, Inc. (NASDAQ:DXCM) earned “Buy” rating by J.P. Morgan on Friday, June 8. Robert W. Baird maintained it with “Outperform” rating and $160 target in Thursday, August 23 report. Northland Capital upgraded the shares of DXCM in report on Wednesday, September 12 to “Market Perform” rating. As per Friday, June 8, the company rating was upgraded by JP Morgan. The stock of DexCom, Inc. (NASDAQ:DXCM) earned “Buy” rating by Berenberg on Monday, August 6. Below is a list of DexCom, Inc. (NASDAQ:DXCM) latest ratings and price target changes.

28/11/2018 Broker: UBS Rating: Neutral New Target: $135 Initiates Coverage On
23/10/2018 Broker: Raymond James Old Rating: Outperform New Rating: Outperform Old Target: $125 New Target: $150 Maintain
19/10/2018 Broker: Goldman Sachs Old Rating: Sell New Rating: Neutral New Target: $125 Upgrade
11/10/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $130 New Target: $150 Maintain
12/09/2018 Broker: Northland Capital Old Rating: Underperform New Rating: Market Perform Upgrade
23/08/2018 Broker: Robert W. Baird Old Rating: Outperform New Rating: Outperform Old Target: $140 New Target: $160 Maintain
23/08/2018 Broker: Stephens Old Rating: Overweight New Rating: Overweight Old Target: $135 New Target: $160 Maintain
23/08/2018 Broker: Canaccord Genuity Old Rating: Buy New Rating: Buy Old Target: $125 New Target: $150 Maintain
15/08/2018 Broker: Bank of America Old Rating: Buy New Rating: Buy Old Target: $127 New Target: $145 Maintain
06/08/2018 Broker: Berenberg Old Rating: Hold New Rating: Buy Upgrade

The stock decreased 0.28% or $0.37 during the last trading session, reaching $129.59. About 6.06M shares traded or 312.11% up from the average. DexCom, Inc. (NASDAQ:DXCM) has risen 98.67% since December 2, 2017 and is uptrending. It has outperformed by 83.05% the S&P500.

DexCom, Inc., a medical device company, together with its subsidiaries, focuses on the design, development, and commercialization of continuous glucose monitoring systems in the United States and internationally. The company has market cap of $11.51 billion. The firm offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers in the hospital for the treatment of patients with and without diabetes. It has a 267.75 P/E ratio. The Company’s products include DexCom G4 PLATINUM system for continuous use by adults with diabetes; DexCom G4 PLATINUM with Share, a remote monitoring system; and DexCom G5 Mobile, a CGM system that directly communicates to a patientÂ’s mobile and its data can be integrated with DexCom CLARITY, which is a next generation cloud reporting software for personalized, easy-to-understand analysis of trends to improve diabetes management.

More notable recent DexCom, Inc. (NASDAQ:DXCM) news were published by: which released: “Noteworthy ETF Inflows: FXH, I, HCA, DXCM – Nasdaq” on November 20, 2018, also with their article: “5 Stocks to Gain as Fed Chair “Blinks” on Rates – Nasdaq” published on November 29, 2018, published: “Earnings Reaction History: DexCom, Inc., 77.8% Follow-Through Indicator, 8.8% Sensitive – Nasdaq” on November 06, 2018. More interesting news about DexCom, Inc. (NASDAQ:DXCM) were released by: and their article: “Dexcom files prospectus to offer 3.87M shares – Seeking Alpha” published on November 21, 2018 as well as‘s news article titled: “DexCom Reports Third Quarter 2018 Financial Results – Business Wire” with publication date: November 06, 2018.

DexCom, Inc. (NASDAQ:DXCM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.